This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Taiji Tsukamoto: Innovator in Cancer Therapy
Introduction
Taiji Tsukamoto is a notable inventor based in Sapporo, Japan. He has made significant contributions to the field of cancer therapy, particularly in renal cell cancer. His innovative work has led to the development of a unique identification marker that responds to interferon therapy.
Latest Patents
Taiji Tsukamoto holds a patent for an "Identification marker responsive to interferon therapy for renal cell cancer." This invention provides a method for detecting a genomic DNA of a human gene from a patient with renal cell cancer. The process involves analyzing the DNA sequence to determine gene polymorphism and evaluating the tumor-suppression effect of interferon therapy using this polymorphism as an indicator. He has 1 patent to his name.
Career Highlights
Tsukamoto is associated with Otsuka Pharmaceutical Company, Limited, where he continues to work on innovative solutions in the medical field. His research focuses on improving treatment options for patients suffering from renal cell cancer.
Collaborations
Some of his notable coworkers include Takayuki Shiratsuchi and Seiji Naito, who have collaborated with him on various projects within the pharmaceutical industry.
Conclusion
Taiji Tsukamoto's contributions to cancer therapy through his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the lives of patients with renal cell cancer positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile